Trial Profile
A retrospective trial of Erlotinib in patients with metastatic, EGFR wild-type, Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Dec 2015 New trial record